239 related articles for article (PubMed ID: 28535157)
1. A meta-analysis of CXCL12 expression for cancer prognosis.
Samarendra H; Jones K; Petrinic T; Silva MA; Reddy S; Soonawalla Z; Gordon-Weeks A
Br J Cancer; 2017 Jun; 117(1):124-135. PubMed ID: 28535157
[TBL] [Abstract][Full Text] [Related]
2. Prognostic role of secreted protein acidic and rich in cysteine in patients with solid tumors.
Ma Y; Chen H; Ma H; Yao Z; Hu J; Ma J; Zhang X; Chen G; Liu Y
Saudi Med J; 2019 Aug; 40(8):755-765. PubMed ID: 31423511
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and clinicopathological value of CXCL12/SDF1 expression in breast cancer: A meta-analysis.
Liu H; Li Z; Deng M; Liu Q; Zhang T; Guo W; Li P; Qiao W
Clin Chim Acta; 2018 Sep; 484():72-80. PubMed ID: 29800557
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of AGR2 expression in solid tumours: a systematic review and meta-analysis.
Tian SB; Tao KX; Hu J; Liu ZB; Ding XL; Chu YN; Cui JY; Shuai XM; Gao JB; Cai KL; Wang JL; Wang GB; Wang L; Wang Z
Sci Rep; 2017 Nov; 7(1):15500. PubMed ID: 29138453
[TBL] [Abstract][Full Text] [Related]
5. CXCR4 as a prognostic biomarker in gastrointestinal cancer: a meta-analysis.
Jiang Q; Sun Y; Liu X
Biomarkers; 2019 Sep; 24(6):510-516. PubMed ID: 31244335
[No Abstract] [Full Text] [Related]
6. CXCL12/SDF1 expression by breast cancers is an independent prognostic marker of disease-free and overall survival.
Mirisola V; Zuccarino A; Bachmeier BE; Sormani MP; Falter J; Nerlich A; Pfeffer U
Eur J Cancer; 2009 Sep; 45(14):2579-87. PubMed ID: 19646861
[TBL] [Abstract][Full Text] [Related]
7. CXCR4, CXCL12 and the relative CXCL12-CXCR4 expression as prognostic factors in colon cancer.
Stanisavljević L; Aßmus J; Storli KE; Leh SM; Dahl O; Myklebust MP
Tumour Biol; 2016 Jun; 37(6):7441-52. PubMed ID: 26678887
[TBL] [Abstract][Full Text] [Related]
8. High hepatocyte growth factor expression in primary tumor predicts better overall survival in male breast cancer.
Qiu SQ; van Rooijen J; Nienhuis HH; van der Vegt B; Timmer-Bosscha H; van Leeuwen-Stok E; Walenkamp AME; van Deurzen CHM; de Bock GH; de Vries EGE; Schröder CP
Breast Cancer Res; 2020 Mar; 22(1):30. PubMed ID: 32188473
[TBL] [Abstract][Full Text] [Related]
9. Role of CXCR4 and SDF1 as prognostic factors for survival and the association with clinicopathology in colorectal cancer: A systematic meta-analysis.
Li YP; Pang J; Gao S; Bai PY; Wang WD; Kong P; Cui Y
Tumour Biol; 2017 Jun; 39(6):1010428317706206. PubMed ID: 28621237
[TBL] [Abstract][Full Text] [Related]
10. CXCR4 expression predicts patient outcome and recurrence patterns after hepatic resection for colorectal liver metastases.
Yopp AC; Shia J; Butte JM; Allen PJ; Fong Y; Jarnagin WR; DeMatteo RP; D'Angelica MI
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S339-46. PubMed ID: 21584832
[TBL] [Abstract][Full Text] [Related]
11. Antihypertensive medications and survival in patients with cancer: a population-based retrospective cohort study.
Holmes S; Griffith EJ; Musto G; Minuk GY
Cancer Epidemiol; 2013 Dec; 37(6):881-5. PubMed ID: 24075077
[TBL] [Abstract][Full Text] [Related]
12. The impact of chemokine receptor CXCR4 on breast cancer prognosis: a meta-analysis.
Xu TP; Shen H; Liu LX; Shu YQ
Cancer Epidemiol; 2013 Oct; 37(5):725-31. PubMed ID: 23763828
[TBL] [Abstract][Full Text] [Related]
13. Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis.
Lin JL; Lin JX; Zheng CH; Li P; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Lin M; Huang CM
BMC Cancer; 2020 Jul; 20(1):638. PubMed ID: 32646396
[TBL] [Abstract][Full Text] [Related]
14. Clinical implication of CXCL12 expression in gastric cancer.
Ishigami S; Natsugoe S; Okumura H; Matsumoto M; Nakajo A; Uenosono Y; Arigami T; Uchikado Y; Setoyama T; Arima H; Hokita S; Aikou T
Ann Surg Oncol; 2007 Nov; 14(11):3154-8. PubMed ID: 17653799
[TBL] [Abstract][Full Text] [Related]
15. Association of genetic polymorphisms of CXCL12/SDF1 gene and its receptor, CXCR4, to the susceptibility and prognosis of non-small cell lung cancer.
Lee YL; Kuo WH; Lin CW; Chen W; Cheng WE; Chen SC; Shih CM
Lung Cancer; 2011 Aug; 73(2):147-52. PubMed ID: 21292343
[TBL] [Abstract][Full Text] [Related]
16. Stromal CXCR4 and CXCL12 expression is associated with distant recurrence and poor prognosis in rectal cancer after chemoradiotherapy.
Saigusa S; Toiyama Y; Tanaka K; Yokoe T; Okugawa Y; Kawamoto A; Yasuda H; Inoue Y; Miki C; Kusunoki M
Ann Surg Oncol; 2010 Aug; 17(8):2051-8. PubMed ID: 20177796
[TBL] [Abstract][Full Text] [Related]
17. CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients.
Goltz D; Holmes EE; Gevensleben H; Sailer V; Dietrich J; Jung M; Röhler M; Meller S; Ellinger J; Kristiansen G; Dietrich D
Oncotarget; 2016 Aug; 7(33):53309-53320. PubMed ID: 27462860
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of MMP Family Members Functions as Prognostic Biomarker for Breast Cancer Patients: A Systematic Review and Meta-Analysis.
Ren F; Tang R; Zhang X; Madushi WM; Luo D; Dang Y; Li Z; Wei K; Chen G
PLoS One; 2015; 10(8):e0135544. PubMed ID: 26270045
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of EZH2 expression in patients with oesophageal cancer: a meta-analysis.
Wang Y; Gao F; Zhao M; Li B; Xing D; Wang J; Yang Y
J Cell Mol Med; 2016 May; 20(5):836-41. PubMed ID: 26859127
[TBL] [Abstract][Full Text] [Related]
20. CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia.
Semaan A; Dietrich D; Bergheim D; Dietrich J; Kalff JC; Branchi V; Matthaei H; Kristiansen G; Fischer HP; Goltz D
Virchows Arch; 2017 Feb; 470(2):185-196. PubMed ID: 27913861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
